title: Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of long-term treatment with arotinolol in patients with idiopathic dilated cardiomyopathy (IDCM).
  
  
  METHODS
  Sixty-three patients with IDCM were evaluated at baseline and after 12-month therapy with arotinolol. The conventional therapy for congestive heart failure was continued throughout the study with arotinolol as the only beta-blocker. Left ventricular function was assessed with the New York Heart Association functional class and two-dimensional echocardiography.
  
  
  RESULTS
  After 12-month arotinolol treatment, there was a significant improvement in left ventricular systolic function. Left ventricular end-systolic dimension significantly decreased from 59.52 +/- 8.83 mm to 50.89 +/- 8.17 mm (P < 0.001). Left ventricular ejection fraction significantly increased from 27.39% +/- 7.94% to 41.13% +/- 9.45% ( P < 0.001). Left ventricular mass index decreased from 150.47 +/- 42.42 g/m2 to 141.58 +/- 34.36 g/m2 (P < 0.01). No adverse events leading to premature discontinuation of study drug occurred.
  
  
  CONCLUSIONS
  In this preliminary study, 12-month arotinolol treatment has a favorable effect on left ventricular function in patients with IDCM, and it is safe and well tolerated.
authors.affiliation: Clinical Pharmacology Center, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing. Fred_Fan2004@yahoo.com.cn
authors.forename: Chao-mei
authors.initials: CM
authors.lastname: Fan
authors.forename: Hong
authors.initials: H
authors.lastname: Yang
authors.forename: Yi-shi
authors.initials: YS
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Xu
authors.forename: Ke-fei
authors.initials: KF
authors.lastname: Dou
authors.forename: Jing-lin
authors.initials: JL
authors.lastname: Zhao
authors.forename: Xian-qi
authors.initials: XQ
authors.lastname: Yuan
authors.forename: Yan-fen
authors.initials: YF
authors.lastname: Zhao
authors.forename: Rong-fang
authors.initials: RF
authors.lastname: Shi
authors.forename: Xiu-qing
authors.initials: XQ
authors.lastname: Du
authors.forename: Na-qiang
authors.initials: NQ
authors.lastname: Lu
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000503:physiopathology; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C024523:arotinolol